Abstracts tagged "mesenchymal stem cells and systemic sclerosis"

Abstract Number: 1861 • 2016 ACR/ARHP Annual Meeting
Modelling the Interaction Between Disease Microenvironment and Mesenchymal Cells in Systemic Sclerosis
Zeinab Taki¹, Bahja Ahmed Abdi², Henrique Rosario³, Sara Zafar⁴, Amy Hart³, Shiwen Xu⁵, Christopher Denton⁶, David Abraham⁶ and Richard J. Stratton⁷, ¹Department of Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ²Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ³Centre of Rheumatology and Connective Tissue disease, University College London, London, United Kingdom, ⁴Centre of Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁵Division of Medicine, Centre for Rheumatology and Connective tissue disease, University College London, London, United Kingdom, ⁶Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁷Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom
Background/Purpose: Systemic Sclerosis (SSc) has complex aetiology with many potential driving forces, one of which is the microenvironment in lesional skin, in which resident mesenchymal stem…
Abstract Number: 1726 • 2014 ACR/ARHP Annual Meeting
Therapeutic Efficacy of Mesenchymal Stem Cells in Diffuse Murine Hypochlorite-Induced Systemic Sclerosis
Alexandre Maria¹, Claire Bony², Karine Toupet², Christian Jorgensen³, Philippe Guilpain⁴ and Daniele Noel⁵, ¹U844, Inserm, Montpellier, France, ²Inserm, Montpellier, France, ³Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, CHU Lapeyronie., Montpellier, France, ⁴Department of Internal Medicine, Montpellier, France, ⁵Inserm U844, UM1, Montpellier, France
Background/Purpose Systemic sclerosis (SSc) is a rare intractable disease with unmet medical need and fibrosis-related mortality. Absence of efficient treatments has prompted to develop novel…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].